Selling, General, and Administrative Costs: Merck & Co., Inc. vs Halozyme Therapeutics, Inc.

SG&A Expenses: Merck vs. Halozyme, 2014-2023

__timestampHalozyme Therapeutics, Inc.Merck & Co., Inc.
Wednesday, January 1, 20143594200011606000000
Thursday, January 1, 20154002800010313000000
Friday, January 1, 2016458530009762000000
Sunday, January 1, 2017538160009830000000
Monday, January 1, 20186080400010102000000
Tuesday, January 1, 20197725200010615000000
Wednesday, January 1, 2020457360008955000000
Friday, January 1, 2021503230009634000000
Saturday, January 1, 202214352600010042000000
Sunday, January 1, 202314918200010504000000
Monday, January 1, 2024154335000
Loading chart...

Cracking the code

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. This chart compares the SG&A expenses of Merck & Co., Inc. and Halozyme Therapeutics, Inc. from 2014 to 2023.

Merck, a global leader, consistently reported SG&A expenses in the range of $9.0 billion to $11.6 billion annually. Despite fluctuations, Merck's expenses remained relatively stable, reflecting its robust operational strategies. In contrast, Halozyme, a smaller biotech firm, saw its SG&A expenses grow significantly, from $35.9 million in 2014 to $149.2 million in 2023, marking a staggering 315% increase.

This divergence highlights the different scales and growth trajectories of these companies. While Merck's expenses are indicative of its established market presence, Halozyme's rising costs suggest aggressive expansion and investment in its operations.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025